An Earnest Proposal for Tackling AMR
Despite global recognition of the threat posed by antimicrobial resistance (AMR), not nearly enough has been done to bring new antibiotics into development. With some drug makers now leaving the antibiotics market altogether, there is an urgent need for a realignment of incentives in this vital area of public health.
https://prosyn.org/759TfXC
LONDON – Under Article 50 of the Treaty of Lisbon, the United Kingdom will leave the European Union on March 29, 2019. Presuming that it does (but even if it does not), the UK government should continue to lead the charge against antimicrobial resistance (AMR), as it has in the past. Specifically, it is time for the UK to join with pharmaceutical companies in piloting a new model of finance for investment in research and development of new antibiotics.